American Diabetes Association 2010 Scientific Sessions

The American Diabetes Association held its 2010 Annual Scientific Sessions from June 25 to 29 in Orlando. The features below highlight some of the news emerging from the meeting. » Investigational Drug Effective as Metformin Add-On » Minor Kidney Damage in Type 1 Diabetes Increases Mortality » The Impact of Exercise Alone on Diabetes Risk » Omega-3 Fatty Acids, Women, & Type 1 Diabetes » Diabetes A Common Cause of Vascular Death Investigational Drug Effective as Metformin Add-On [back to top] The Particulars: Dapagliflozin is an investigational selective sodium-glucose cotransporter-2 inhibitor. Dapagliflozin is thought to reduce renal glucose reabsorption so that excess blood glucose is instead excreted into the urine. The mechanism of action is independent of insulin. A phase III trial was conducted in metformin patients who had not achieved adequate glucose control. Data Breakdown: All patients were randomized to placebo or one of three doses of dapagliflozin (2.5 mg, 5.0 mg, or 10.0 mg), and patients also continued taking metformin. Mean glycosylated hemoglobin decreased significantly for patients on any of the three doses of dapagliflozin when compared with those on placebo. At 24 weeks, more patients in the dapagliflozin groups achieved a therapeutic response, which was defined as A1C levels of less than 7% (33% to 40.6% in dapagliflozin groups vs 25.9% in controls). Decreases in fasting plasma glucose concentration and weight loss were also significantly greater in the dapagliflozin groups when compared with placebo. Take Home Pearls: Adding dapagliflozin to metformin may improve glycemic control in patients with diabetes who are not responsive to metformin monotherapy. The addition of dapagliflozin to metformin may provide a new...